Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: A retro-prospective observational study.

Maria Livia Del GiudiceAlessandro GozzettiElisabetta AntonioliIrene AttucciLudovica PengueRaffaella Cassano CassanoFrancesco GhioEnrico OrciuoloMartina SimoncelliMonica BocchiaSara GalimbertiGabriele Buda

Published in: European journal of haematology (2022)

Kd56 is an effective and well tolerated regimen in highly pretreated and elderly patients with a good safety profile.

Keyphrases

multiple myeloma
middle aged
low dose
high dose
community dwelling